Introduction
============

Nearly 600 million people worldwide will have type 2 diabetes by 2030.[@ref1] Innovation in delivering effective clinical care to these people is therefore an urgent global priority. To reduce the risk of long term macrovascular and microvascular complications,[@ref2] UK, European, and US guidelines recommend early adoption of insulin as part of stepwise treatment intensification to bring glycated haemoglobin (HbA1c) below a general target of 7% (53 mmol/mol).[@ref3] [@ref4] [@ref5] [@ref6] Insulin initiation is often delayed, however, particularly in primary care,[@ref7] where implementation is not widespread despite being recommended as part of routine clinical management of type 2 diabetes.[@ref6] The mean HbA1c of people with type 2 diabetes before starting insulin is typically 1.5-2.0% above target: 9.3% (78 mmol/mol) in the UK,[@ref8] 8.6% (70 mmol/mol) in a study in the US,[@ref9] 8.9% (74 mmol/mol) in a large, multicountry primary care study,[@ref10] and 9.4% (79 mmol/mol) in a community study in Australia (after a median diabetes duration of 8.1 years).[@ref11]

Delay in treatment intensification by healthcare professionals, despite evidence that intensification is warranted and effective,[@ref12] is a major barrier to initiating insulin in people with type 2 diabetes.[@ref13] The delay can be due to health professional factors[@ref14] (for example, concerns about hypoglycaemia risk, lack of confidence or skills in insulin initiation or titration), health system factors[@ref15] (competing priorities in busy, reactive primary care settings), and patient related factors (psychological resistance to insulin inititation[@ref16]). Supporting and embedding insulin initiation in routine primary care practice is an important first step in potentially reducing referrals to costly secondary care, and in supporting timely, early optimisation of treatment, to better achieve glycaemic targets.

Our trial investigated the effectiveness of a new model of care: the Stepping Up model, which was designed to support insulin initiation in primary care among people with type 2 diabetes for whom it is clinically indicated. The Stepping Up model of care is built around an enhanced, reconfigured role for primary care practice nurses,[@ref17] who represent a rapidly growing section of the workforce and have a substantial role in the management of chronic conditions. Our approach was to train and mentor nurses to enhance their knowledge, skills, and confidence in discussing and implementing insulin initiation within the practice as a part of routine care. Furthermore, we aimed to set simple clinical protocols on insulin initiation. To implement these behaviour changes in professionals, we drew on normalisation process theory[@ref18] and the results of pilot studies.[@ref17] [@ref19] Our aim was to address clinician and system level barriers to timely insulin initiation, and to normalise insulin initiation as part of standard primary care practice. We hypothesised that HbA1c would improve among participants in intervention arm practices, facilitated through timely insulin initiation, compared with the control arm. Furthermore, based on previous research,[@ref20] [@ref21] we expected no major negative effect on participants' general emotional wellbeing (depressive symptoms).

Methods
=======

Study design and participants
-----------------------------

The study design and protocol have been described previously.[@ref22] In summary, we conducted a 12 month, two arm, non-blinded cluster randomised controlled trial, consistent with CONSORT guidelines,[@ref23] to investigate the effectiveness of the Stepping Up model of care compared with usual care.

General practices in Victoria, Australia, were eligible if they had at least one consenting general practitioner and practice nurse and could identify at least one eligible patient participant: adults with type 2 diabetes with above target HbA1c (≥7.5% (58 mmol/mol)) in the past six months who were already prescribed maximum oral treatment (at least two oral hypoglycaemia agents at maximum doses) or if their GP judged that insulin would be clinically appropriate. Patients were ineligible if they were aged more than 80 years, were already using insulin, had an estimated glomerular filtration rate \<30 mL/min/1.73m^2^, were unable to give informed consent, or had a complex debilitating medical condition, such as severe mental illness, end stage cancer, or unstable cardiovascular disease.

Our original protocol was based on 58 practices and an average cluster size of 5. From our early recruitment experience and what was an achievable sample size, we subsequently revised this to 74 practices and an average cluster size of 3 (appendix files).

Randomisation
-------------

The unit of randomisation was the primary care practice. The study statistician computer generated stratified block randomisation sequences with varying block sizes (4, 6, and 8) before recruitment. Practices were stratified by size (≤2 versus \>2 full time equivalent GPs), setting (private practice versus community health centre), and participation (or not) in type 2 diabetes quality improvement programmes (the Australian Primary Care Collaborative). After providing consent and recruiting at least one eligible patient, practices were randomised to intervention or usual care. We used this index case method[@ref24] in all practices because our previous experience suggested that delaying randomisation of a cluster until all patients had been recruited risked loss of engagement of GPs.[@ref25] The research team then assisted practices to continue to identify and recruit patient participants (through searching the practice medical record database). This meant that allocation concealment after the index case was recruited was not possible for the GP and practice nurse. To minimise potential bias, participating patients were not informed of their study allocation until after they had provided consent. Blinding of GP, practice nurse, and patient was also not possible given the pragmatic nature of the intervention.

Intervention
------------

The Stepping Up model of care, described elsewhere,[@ref17] [@ref22] involved a reorientation of existing resources. Firstly, it included an enhanced role for the practice nurse in leading the discussion with patients about intensifying treatment through insulin initiation and titration. Secondly, the model of care set simple clinical protocols for insulin initiation and up-titration. Thirdly, the model of care reoriented the role of the specialist registered nurse with diabetes educator credentials in mentoring the practice nurse, rather than providing direct patient care. Intervention practices had an in-practice briefing and training session of 60-90 minutes for GPs and practice nurses, after which patients with confirmed eligibility and completed baseline data were invited to consult their GP for an assessment to discuss treatment intensification and referral to the practice nurse. Practice nurses did not prescribe insulin or manage insulin dosing without liaison with the GP, based on the legal scope of practice for generalist practice nurses in Australia.

Our model of care involved the acknowledgment and discussion with patients of the advantages and disadvantages of starting insulin treatment, including weight gain. We modelled shared decision making as a part of the intervention training, drawing on the principles of motivational interviewing. This set the scene for encouraging practitioners in intervention practices to approach participating patients with equipoise in relation to starting insulin. The intervention was necessarily brief in this pragmatic trial; however, we included in it guidance and checklists for GPs and practice nurses to discuss the pros and cons of insulin treatment and to elicit patient concerns and expectations, while also openly acknowledging and accepting that some patients may choose not to start insulin.

The role of the registered nurse with diabetes educator credentials in supporting and mentoring the practice nurse, and of the practice nurse in leading the discussion and implementation of insulin treatment with the patient in liaison with the GP, is outlined elsewhere.[@ref15] [@ref20] Titration protocols were based on fasting blood glucose levels and use of a three day, 7 point blood glucose profile[@ref26] to identify the meal with the greatest postprandial excursion (see appendix files). We gave no additional instructions, so the GP had clinical autonomy regarding the management of oral hypoglycaemia agents. Practice nurses and GPs were encouraged to see patients as often as thought to be clinically appropriate over a period of up to 12 months, drawing as needed on the study registered nurse with diabetes educator credentials for mentoring and support, even if the patient remained undecided about, or had decided against, starting insulin. Further details about the intervention can be found in the referenced papers and appendices (see appendix files).

We gave control arm practices a copy of the Australian type 2 diabetes management guidelines[@ref27] and offered them training in the Stepping Up model of care after the 12 month follow-up of patient participants was complete.

Patient involvement
-------------------

We sought feedback from participants after conducting an intervention pilot study[@ref15] and used this feedback to refine the model of care. We sought further participant feedback in a pilot of the data collection forms. Throughout the main trial we communicated with patient participants through a regular newsletter that included aggregate data about study progress and opportunities to provide feedback to the study team. We assessed the burden of the intervention on patients through interviews conducted at the end of the trial, as part of process evaluation (to be reported elsewhere). This evaluation was led by the Chronic Illness Alliance, a consumer advocacy organisation that has been a long term collaborator of our research group. We have thanked all participants for their involvement in the trial, and will provide, at a later date, a final summary report of the trial outcomes. Participants have access to the study website where all published results will be publicly available.

Endpoints and data collection
-----------------------------

Our intervention targeted a process of care (insulin initiation); however, we chose a clinically meaningful disease outcome at an individual patient level as a primary endpoint: change (from baseline to 12 months) in HbA1c, measured as a continuous variable. We registered our primary outcome as an absolute HbA1c reduction of 0.5% in the intervention group compared with the control group. Measurement of HbA1c was performed at pathology laboratories aligned with the Diabetes Control and Complications Trial and the result was communicated to clinicians and patients as part of usual clinical care. Researchers retrieved these data from medical records or directly from pathology laboratories. Secondary endpoints included the proportion of participants who transitioned to insulin (this was amended from the original protocol where rate of insulin initiation was used, which proved impractical given the small cluster size in the study), the proportion who achieved a target HbA1c of ≤7.0% (53 mmol/mol) at 12 months, and change (from baseline to 12 months) in depressive symptoms (nine item patient health questionnaire, PHQ-9),[@ref28] diabetes specific distress (problem areas in diabetes scale, PAID),[@ref29] and generic health status (assessment of quality of life instrument, AQoL-8D).[@ref30] The Appendix files show differences between the registered outcomes reported here and those registered in the trial registry, and justification and explanation for any changes made. We also collected data on healthcare utilisation and costs, to be reported elsewhere.

All participants were provided with a blood glucose meter (Performa Nano; Roche Diagnostics) and instructed on its use. Subsidised low cost blood glucose testing strips were available through the National Diabetes Service Scheme.[@ref31] Data were uploaded from the meter at six and 12 months to a secure server.

Statistical analysis
--------------------

Our statistical analysis plan has been published elsewhere.[@ref22] In brief, our sample size of 224 patients from 74 general practices (averaging three patients per practice) allowed us to detect an absolute 0.5% mean HbA1c difference at 12 months between control and intervention arms with 80% power and standard deviation of 1 using a two sided α of 0.05. Data were analysed using Stata 13 (StataCorp, TX, USA). Descriptive statistics were used to summarise GP, practice nurse, and patient characteristics for the two study arms. Parametric data are reported as means (standard deviations) and non-parametric data as medians (interquartile ranges). Categorical data are reported as numbers (percentages). The individual patient was the unit of analysis and the analytical methods allow for clustering of patients within the practices. We compared binary outcomes between the two study arms with marginal logistic modelling using generalised estimating equations with robust standard errors and adjustment for baseline measures and clustering. Mixed effects linear regression was used to determine predictors for continuous outcomes, adjusting for baseline measures and clustering at the practice level. A *t* test for proportions was used to compare the use of non-insulin agents between arms at 12 months, and a Wilcoxon ranked sum test was used to compare the number of days since insulin was started between control and intervention groups. Analyses were conducted on an intention to treat basis. All participants gave informed consent before enrolment.

Results
=======

Participating practices and patients
------------------------------------

Between October 2012 and January 2014, 93 primary care practices expressed interest and identified 521 potentially eligible patients (fig 1[](#f1){ref-type="fig"}). Subsequently, 19 practices did not consent any eligible patients, leaving 74 participating practices for randomisation. Two hundred and 50 five of the potentially eligible patients were subsequently found to be ineligible at screening (n=156) or did not respond to the invitation letter (n=99). By April 2014, the 74 practices had identified and consented 266 eligible participants (73% of potentially eligible patients identified).

![**Fig 1** CONSORT diagram for the Stepping Up randomised control trial](furj034563.f1_default){#f1}

Table 1[](#tbl1){ref-type="table"} shows the baseline characteristics of practices, GPs, practice nurses, and participants with type 2 diabetes. Of the total sample, 248 (93%) completed the 12 month follow-up for the primary endpoint. No differences in baseline characteristics were observed between study completers and non-completers, except for a higher proportion of women not completing than men (11 *v* 7).

###### 

Baseline characteristics of participating practices, health professionals, and adults with type 2 diabetes in Stepping Up model of care trial. Values are numbers (percentages) unless stated otherwise

  Characteristics                                                                  Intervention arm   Control arm
  -------------------------------------------------------------------------------- ------------------ ----------------
  Practices                                                                                           
  Primary care practices                                                           36 (49)            38 (51)
  Type of practice:                                                                                   
   Private practice                                                                27 (75.0)          31 (81.6)
   Corporate practice                                                              7 (19.4)           5 (13.2)
   Community health centre                                                         2 (5.6)            2 (5.3)
  Location of practice:                                                                               
   Major city                                                                      26 (72.2)          21 (55.3)
   Inner regional area                                                             9 (25.0)           13 (34.2)
   Outer regional area                                                             1 (2.8)            4 (10.5)
  Median (IQR) No of physicians per practice                                       5 (4-9.5)          5 (4-9)
  Median (IQR) No of practice nurses per practice                                  2.5 (2-3.5)        2 (1-4)
  Registered nurse with credentials for diabetes educator on site                  12 (33.3)          14 (36.8)
  Median (IQR) No of patients per full time equivalent general practitioner^\*†^   1738 (1176-2727)   1316 (911-1726
  General practitioners                                                            83 (51.2)          79 (48.8)
  Mean (SD) age (years)^‡^                                                         48.8 (9.9)         49.7 (11.2)
  Women                                                                            34 (41.0)          27 (34.2)
  Working hours/week^‡^                                                            36.6 (10.5)        37.3 (11.6)
  Median (IQR) years of experience                                                 19 (8-26)          20 (7-30)
  Experience with insulin initiation in preceding 12 months^§^                     48 (60.0)          36 (46.2)
  Practice nurses                                                                  48 (46.6)          55 (53.4)
  Mean (SD) age (years)^¶^                                                         44.7 (10.2)        46.0 (9.9)
  Women                                                                            48 (100)           55 (100)
  Diabetes educator training                                                       6 (12.5)           7 (12.7)
  Experience with insulin initiation in preceding 12 months                        16 (33.3)          16 (29.1)
  Adults with type 2 diabetes                                                      151 (56.8)         115 (43.2)
  Mean (SD) age (years)                                                            61.7 (9.7)         62.0 (10.6)
  Women                                                                            62 (41.1)          41 (35.7)
  Highest level of education:                                                                         
   Primary or less                                                                 14 (9.3)           12 (10.4)
   Secondary or trade                                                              101 (66.9)         83 (72.2)
   Tertiary                                                                        36 (23.8)          20 (17.4)
  Employed                                                                         67 (44.4)          50 (43.5)
  Healthcare card holder                                                           75 (49.7)          62 (53.9)
  Median (IQR) diabetes duration (years)                                           8 (5-12)           9 (5-14)
  Median (IQR) HbA1c (%)                                                           8.7 (8.1-9.7)      8.5 (8-9.6)
  Median (IQR) HbA1c (mmol/mol)                                                    72 (65-83)         69 (64-81)
  Median (IQR) No of medical conditions                                            3 (2-5)            3 (2-5)
  Median (IQR) No of drugs                                                         6 (5-10)           7 (5-10)
  Median (IQR) drug adherence rating scale^\*\*^                                   29 (26-30)         29 (27-30)
  Diabetes complications^††^:                                                                         
   Microvascular                                                                   17 (11.3)          16 (13.9)
   Macrovascular                                                                   22 (14.6)          21 (18.3)
  Total cholesterol(mmol/L)^‡‡^                                                    4.3 (1.0)          4.2 (1.1)
  Triglycerides (mmol/L)^†‡‡^                                                      1.9 (0.1)          2.3 (1.4)
  LDL cholesterol (mmol/L)^§§^                                                     2.3 (0.9)          2.1 (0.9)
  HDL cholesterol (mmol/L)^¶¶^                                                     1.2 (0.3)          1.1 (0.3)
  Estimated glomerular filtration rate^\*\*\*^                                     79.4 (14.4)        78.8 (14.6)
  Blood pressure (mm Hg):                                                                             
   Systolic                                                                        134.6 (15.7)       133.5 (15.2)
   Diastolic                                                                       79.6 (11.1)        78.5 (9.5)

IQR=interquartile range; LDL=low density lipoprotein cholesterol; HDL=high density lipoprotein.

\*Data available for 67 practices (33 intervention, 34 control).

†Statistically significant difference between control and intervention groups.

‡Data available for 161 GPs (82 intervention, 79 control).

§Data available for 158 GPs (84 intervention, 74 control).

¶Data available for 100 practice nurses (46 intervention, 54 control).

\*\*Data available for 261 patients (149 intervention, 112 control).

††No (%) with at least one complication.

‡‡Data available for 256 patients (144 intervention, 112 control).

§§Data available for 222 patients (130 intervention, 92 control).

¶¶Data available for 233 patients (134 intervention, 99 control).

\*\*\*Data available for 261 patients (147 intervention, 114 control).

Primary and secondary endpoints
-------------------------------

Table 2[](#tbl2){ref-type="table"} shows the primary and secondary endpoints. At 12 months there was a statistically and clinically significant difference between study arms in terms of change in HbA1c (mean difference: −0.6%, 95% confidence interval −0.9% to −0.3%, P\<0.001), favouring the intervention. This is consistent with achieving our registered primary outcome of an absolute HbA1c reduction of 0.5% in the intervention group compared with the control group. The majority of this change in HbA1c seen in both arms was achieved by six months (fig 2[](#f2){ref-type="fig"}).

###### 

Primary and secondary endpoints of Stepping Up model of care trial: biochemical, clinical, and psychological outcomes. Values are mean (SD) or median (interquartile range) unless stated otherwise

  Endpoints                                                                                Intervention arm   Control arm     Adjusted data for baseline measure and clustering   
  ---------------------------------------------------------------------------------------- ------------------ --------------- --------------------------------------------------- ---------
  HbA1c (%):                                                                                                                                                                      
   Baseline                                                                                8.7 (8.1-9.7)      8.5 (8-9.6)                                                         
   Follow-up                                                                               7.4 (6.9-8.2)      8.0 (7.1-9.0)                                                       
   Change                                                                                  −1.3 (1.4)         −0.6 (1.5)      −0.6 (−0.9 to −0.3)                                 \<0.001
  No (%) of participants using insulin:                                                                                                                                           
   Follow-up                                                                               105 (69.5)         25 (21.7)       8.3\* (4.5 to 15.4)                                 \<0.001
  No (%) of participants with HbA1c ≤53 mmol/mol (7%):                                                                                                                            
   Follow-up                                                                               54 (35.8)          24 (20.9)       2.2\* (1.2 to 4.3)                                  0.02
  Depressive symptoms (PHQ-9)^†^:                                                                                                                                                 
   Baseline                                                                                3 (1-7)            2 (1-6.5)                                                           
   Follow-up                                                                               2 (0-5)            2 (0-5)                                                             
   Change                                                                                  −1.1 (3.5)         −0.1 (2.9)      −0.8 (−1.6 to −0.01)                                0.047
  No (%) of participants with moderate-severe depressive symptoms (PHQ-9 total: ≥10)^‡^:                                                                                          
   Baseline                                                                                22 (15.1)          15 (13.5)                                                           
   Follow-up                                                                               19 (12.8)          15 (13.3)       0.82\* (0.3 to 2.2)                                 0.69
  Diabetes specific distress (PAID)^§^:                                                                                                                                           
   Baseline                                                                                15 (6.3-31.3)      12.5 (5-23.8)                                                       0.14
   Follow-up                                                                               8.8 (3.8-22.5)     10 (2.5-23.8)                                                       
   Change                                                                                  −5.6 (15.5)        −2.4 (15.4)     −1.9 (−5.1 to 1.3)                                  0.24
  No (%) of participants with severe diabetes specific distress (PAID total: ≥40)^‡^:                                                                                             
   Baseline                                                                                25 (16.8)          14 (12.4)                                                           
   Follow-up                                                                               18 (12.1)          12 (10.4)       1.0\* (0.4 to 2.3)                                  0.93
  Health status (AQoL-8D) physical component score^¶^:                                                                                                                            
   Baseline                                                                                0.63 (0.20)        0.61 (0.21)                                                         
   Follow-up                                                                               0.66 (0.21)        0.64 (0.21)                                                         0.52
   Change                                                                                  0.03 (0.15)        0.02 (0.13)     0.01 (−0.03 to 0.04)                                0.64
  Health status (AQoL-8D) mental component score^¶^:                                                                                                                              
   Baseline                                                                                0.45 (0.20)        0.45 (0.22)                                                         
   Follow-up                                                                               0.48 (0.21)        0.45 (0.22)                                                         
   Change                                                                                  0.04 (0.16)        −0.002 (0.13)   0.04 (0.002 to 0.08)                                0.04
  Weight (kg):                                                                                                                                                                    
   Baseline                                                                                90.8 (19.6)        94.6 (18.9)                                                         
   Follow-up                                                                               92.5 (20.1)        93.5 (18.9)                                                         
   Change                                                                                  1.7 (5.2)          −1.1 (5.1)      2.8 (1.5 to 4.0)                                    \<0.001

\*Odds ratio.

†Patient health questionnaire 9. Range of possible scores: 0-27. A total score of ≥10 indicates at least moderate depressive symptoms. Data available for 261 patients at baseline (149 intervention, 112 control) and 263 at 12 months (149 intervention, 114 control; intention to treat (ITT) population).

‡Data available for 257 patients at baseline (146 intervention, 111 control) and 261 at 12 months (148 intervention, 113 control; ITT).

§Problem areas in diabetes. Range of possible scores: 0-100. A score of ≥40 indicates severe diabetes related distress. Data available for 262 patients at baseline (149 intervention, 113 control) and 264 at 12 months (149 intervention, 115 control; ITT).

¶Assessment of quality of life. Maximum possible score is 1. Higher scores indicate better generic health status. Data available for 262 patients at baseline (149 intervention, 113 control) and 263 at 12 months (149 intervention, 114 control; ITT).

![**Fig 2** Change in primary endpoint at six and 12 months. HbA1c: Glycated haemoglobin](furj034563.f2_default){#f2}

In the intervention arm, 105/151 (70%) patients started insulin (102 were using insulin at 12 months), whereas in the control arm, 25/115 (22%) started insulin (24 were using insulin at 12 months). The median number of days from baseline assessment to insulin initiation in intervention and control group patients who started insulin was 32 (interquartile range 11.5-134.5) days and 85 (63-191) days, respectively, (statistically significant difference: two sample Wilcoxon rank sum test; P=0.005). In the intervention arm, 17 (11%) patients had started rapid acting insulin at 12 months, compared with one patient in the control arm (P\<0.001). Further data on insulin use in participants are available in the appendix files.

Target HbA1c (≤7% (53 mmol/mol)) was achieved by 54 (36%) intervention participants (32 of whom were using insulin at 12 months) and 22 (19%) control participants (two of whom had started insulin): odds ratio 2.2 (95% confidence interval 1.2 to 4.3), P=0.02. Twenty two (15%) intervention participants and 20 (17%) control participants achieved target HbA1c without starting insulin.

At 12 months, depressive symptoms had not worsened and there was no statistically significant difference between arms in the mean change (patient health questionnaire-9: −1.1 (SD 3.5) *v* −0.1 (2.9)). There was a statistically significant difference in mental health (AQoL mental component summary: 0.04 (0.16) *v* −0.002 (0.13)), favouring the intervention, but no significant difference in physical health (AQoL physical component summary: 0.03 (0.15) *v* 0.02 (0.13)) or diabetes specific distress (PAID: −5.6 (15.5) *v* −2.4 (15.4)). There was no statistically significant difference between arms in the proportion of participants experiencing moderate to severe depressive symptoms or severe diabetes specific distress (table 2[](#tbl2){ref-type="table"}), nor was there any difference by insulin initiation (Wilcoxon rank sum test; P=0.98). No significant difference was found in PHQ-9, AQoL, or PAID scores when comparing participants who started insulin with those who did not (data not shown).

At 12 months there was an average weight gain in the intervention arm and an average weight loss in the control group (1.7 (SD 5.2) kg *v* −1.1 (5.1), mean difference 2.8 (95% confidence interval 1.5 to 4.0) kg). There were no statistically significant differences in blood pressure or other biochemical measures between arms at follow-up, with the exception of triglycerides, which remained higher in the control group.

At baseline, participants were using a mean of 2.0 (SD 0.6) classes of non-insulin hypoglycaemic agents, with no significant difference between arms (*t* test, P=0.89). The majority of patients were prescribed metformin (93% across both arms) and sulfonylureas (63% across both arms). There was no significant difference in the prescription of individual drug classes by study arm. The mean number of classes of non-insulin hypoglycaemic agents being used at 12 months was higher in the control arm compared with the intervention arm (2.3 (SD 0.1) *v* 1.9 (0.1); P=0.01). A higher proportion of people in the control group used dipeptidyl peptidase 4 inhibitors than in the intervention group at 12 months (table 3[](#tbl3){ref-type="table"}).

###### 

Classes of non-insulin drugs at 12 months

  Drug classes                                No (%) in intervention arm (n=146)   No (%) in control arm (n=108)   P value^\*^
  ------------------------------------------- ------------------------------------ ------------------------------- -------------
  Metformin                                   133 (91.1)                           96 (88.9)                       0.56
  Sulphonylurea                               75 (51.4)                            64 (59.3)                       0.21
  Acarbose                                    3 (2.1)                              2 (1.9)                         0.91
  Dipeptidyl peptidase 4 inhibitors^†^        25 (17.1)                            38 (35.2)                       0.001
  Glitazones                                  6 (4.1)                              5 (4.6)                         0.8411
  Sodium-glucose cotransporter 2 inhibitors   2 (1.4)                              2 (1.9)                         0.76
  Glucagon-like peptide 1 agonists            9 (6.2)                              7 (6.5)                         0.92

\**t* test of proportions.

†At time of the trial dipeptidyl peptidase 4 inhibitors were not subsidised for use with insulin.

Practices in the intervention arm received 183 mentoring support visits from the study registered nurse with diabetes educator credentials (mean visits per practice 5.2 (range 1-8)). Thirty two per cent (48/151) of participants in intervention practices completed at least one three day, 7 point structured blood glucose monitoring profile over the 12 month study. Practice nurses estimated the time they spent on the study (clinical interactions with participating patients and research tasks). On a per practice basis, 23 control practices and 27 intervention practices reported a median of 1.5 (interquartile range 0-3.6) hours and 18 (9-20.9) hours, respectively.

Overall, 58% of people in the control group were recruited before practice randomisation compared with 45% in the intervention group (significant difference P=0.033). Sensitivity analysis was conducted to explore whether there was any difference at baseline between patients who were recruited before and after randomisation of the practices. No statistically significant differences were found. Mixed effects linear regression was used to determine the impact of the intervention, adjusting for clustering at the practice level for each of these groups. Treatment effect in terms of the primary outcome remained significant in both groups (treatment effect: −0.57 (95% confidence interval −1.1 to −0.05), P=0.03 and −0.98 (−1.49 to −0.48), P\<0.001 for patients assessed before and after randomisation, respectively).

Adverse events
--------------

No severe hypoglycaemic events (those that would require third party assistance for recovery) or other adverse events were reported in either study arm.

Discussion
==========

Our model of care changed clinical practice, with most participants in the intervention arm starting insulin, producing a clinically and statistically significant improvement in glycaemia among adults with type 2 diabetes managed in primary care. This was despite a higher patient to GP ratio in intervention practices, and was achieved safely, with no severe hypoglycaemic events, and without deterioration in emotional wellbeing or health status. Our results indicate that, with appropriate support and redesign of the practice system, insulin initiation can become part of routine diabetes management in primary care, obviating the need to refer to specialist services with geographical, cost, and accessibility barriers.

Strengths and limitations of this study
---------------------------------------

A strength of our study is the robust theoretical and empirical base to our intervention. Our pragmatic trial of a complex intervention addressed several known barriers to overcoming delay in starting insulin treatment. For example, an intentional component of our system redesign was reorienting the practice nurse and registered nurse with diabetes educator credentials roles, allowing additional time to be spent with patients, within existing resources. Other strengths include the cluster randomised design, minimising the risk of contamination, and our excellent rate of participant retention (93%).

Our study had limitations. Firstly, practices were randomised after the first consenting patient was identified, raising the possibility of selection bias. However, the balance in key patient characteristics between the study arms means that any such bias was minimal. Secondly, while a smaller cluster size is generally preferable in a cluster randomised trial, the relatively large variation in the cluster sizes in our study may make statistical adjustments for clustering less effective, in particular when the number of clusters is small. Thirdly, our sample may not have been fully representative of the broader population of adults with type 2 diabetes managed in primary care for whom insulin is clinically indicated. Overall, less than 15% of our sample had severe diabetes specific distress or moderate to severe depressive symptoms, a lower rate than in a recent national Australian sample.[@ref32] We will explore implementation fidelity and variation in more detail through a qualitative process evaluation in a subsequent paper. Finally, our drugs and hypoglycaemia data were derived from GP records and subject to the same accuracy limitations of any routinely collected clinical dataset. Hypoglycaemia is typically underestimated[@ref33] and is likely to be under-reported in routine medical records.[@ref34] In particular, severe hypoglycaemia is serious but relatively rare and may not have been detected in our study, given our sample size.

Comparison with other studies
-----------------------------

Only two other trials have tested interventions to change clinical practice in this way. The AIM\@GP trial showed no improvement in insulin prescribing rates or glycated haemoglobin.[@ref35] It provided scheduled and ongoing telephone support from a specialist diabetes educator and the option to refer patients to an offsite community pharmacist for a one hour insulin initiation session. Our intervention differed in that it was based completely in the familiar environs of patients' own primary care practices, built on existing relationships and resources (with the practice based practice nurses), and provided an immediate pathway for the GP to delegate this clinical task. A UK study, using a before and after evaluation design, showed improved HbA1c (−1.4%) at six months in patients who started insulin,[@ref36] similar in magnitude to the improvement in our study. That intervention combined education with face to face and telephone support from a registered nurse with diabetes educator credentials for GPs and practice nurses and involved full day, offsite training for both GPs and practice nurses. In contrast, our intervention used a brief (60-90 minute) onsite training session incorporated into the daily running of the practice with flexible support from the registered nurse with diabetes educator credentials, as required. Consistent with previous research,[@ref37] our study participants did not report worse psychological outcomes at follow-up, suggesting that insulin treatment can be initiated in primary care for people with type 2 diabetes without impairing their emotional wellbeing. In fact, at 12 months, the reduction in depressive symptoms in intervention arm participants was significantly greater than that in the control arm. Insulin initiation (across both arms) did not affect depressive symptoms, diabetes specific distress, or generic health status at 12 months.

Conclusions and policy and practice implications
------------------------------------------------

Our pragmatic trial findings have important implications for the organisation of healthcare and for health policy. Our model of care is based on an enhanced role for a practice nurse and would not be feasible where primary care doctors work in solo practice without access to a practice nurse. Nevertheless, even in high resource settings, where the move to multidisciplinary primary healthcare teams is growing---for example, through the growth of the Medical Home movement,[@ref38] our study suggests that simply having access to a practice nurse will not increase the rate of appropriate insulin initiation. To make the best use of resources, primary care workforce models need to be developed and implemented to reorient the way specialists (registered nurse with diabetes educator credentials and endocrinologists) offer support to primary care teams that include well supported and resourced primary care nurses. Changes in the role of registered nurse with diabetes educator credentials is occurring in some health systems,38 and our study provides evidence of the effectiveness and safety of such models of care. Rather than waiting for referrals, specialist services need to offer proactive, tailored secondary consultation, liaison, and mentoring services that are flexible and supportive of the needs of primary care practitioners and patients. Scaling up the model of care in metropolitan centres would require engaging with hospitals and other health services in reorienting the role of registered nurse with diabetes educator credentials currently employed in direct patient care. Investigation of e-health modalities (for example, online training, support, and video consultations) could support implementation of this model of care in more distant rural or remote settings.

Our trial findings also have implications for clinical practice. The issue around personalising glycaemic targets and treatments is an important and emerging consideration in the care of people with type 2 diabetes. When our trial started, there was vigorous debate about the need for caution in setting lower targets. In addition, our exclusion criteria ruled out participants for whom a higher target would definitely be considered. Collecting reliable data on duration of cardiovascular disease, severe hypoglycaemia, and hypoglycaemic unawareness did not prove feasible in this setting. We therefore decided to use the general target of 7%. Debate continues about the advantages and disadvantages of intensifying treatment for people with type 2 diabetes who have the HbA1c levels mandated in our study. Our findings suggest that the Stepping Up model of care builds clinical capacity within GP and practice nurse teams to undertake the work of insulin initiation. However, the model of care did not mandate a dogmatic approach to such changes in treatment. It is worth noting the major change in HbA1c was achieved at six months, and that even in intervention practices, only 35% of participants with type 2 diabetes achieved the general HbA1c target of \<7% (53 mmol/mol), suggesting that practitioners and patients were judicious in the way they approached progressive treatment intensification, within the new model of care.

Our clinical protocols and algorithms were focused solely on insulin. It is worth noting that NPH (neutral protamine hagedorn) insulin remains widely used and that the added costs of analogueue insulins where NPH can be used without problem is still subject to debate. While we did not prespecify weight gain as a secondary outcome, this is an adverse effect of insulin treatment and we have chosen to report it. While insulin is still regarded as an essential treatment option, as the range of glycaemic treatments grows, clinical algorithms become more complex.[@ref5] Future research needs to explore the capacity to generate recommendations for real time personalised treatment intensification that incorporate this increasing complexity,[@ref39] to be used as part of the practice nurse led model of care. Future research could also address the extent to which improvements in glycaemic levels are maintained, and the extent to which the model of care is sustained in routine clinical practice. In particular, research could explore use of the model of care to specifically support early adoption of insulin treatment to achieve glycaemic targets early in people with recently diagnosed type 2 diabetes.

The global epidemic of type 2 diabetes demands innovation in care delivery. Delaying insulin initiation when clinically indicated is neither ethical nor effective. Furthermore, health systems will not cope with demand if insulin initiation remains anchored in specialist centres, nor will they be able to respond to the imperative to achieve glycaemic targets early in people with recently diagnosed type 2 diabetes. Thus our pragmatic, translational study has important implications across health systems globally for the organisation of care for people with type 2 diabetes. Our effective model of care has the potential to improve outcomes while making better use of scarce healthcare resources.

### What is already known on this topic

1.  Achieving and maintaining glycaemic targets early in type 2 diabetes improves long term outcomes

2.  There are barriers to early stepwise progressive treatment intensification to achieve glycaemic targets in primary care, particularly when starting insulin

3.  Interventions have had limited success in overcoming the delay in starting insulin treatment and changing clinical practice, in part because system level barriers are not addressed

### What this study adds

1.  Our model of care intervention changed clinical practice, with more patients in intervention arm practices starting insulin, with an overall benefit in terms of HbA1c reduction, achieved without serious adverse events or any worsening in depressive symptoms

2.  The theoretical base and flexible implementation are important characteristics of our intervention

3.  Our model of care used existing resources and thus has important implications for policymakers, funders, and practitioners seeking innovative ways to provide the best care for people with type 2 diabetes in primary care
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